Content about Watson Labs

January 22, 2013

The Food and Drug Administration has approved a generic contraceptive made by Lupin Pharmaceuticals, the drug maker said Tuesday.

BALTIMORE — The Food and Drug Administration has approved a generic contraceptive made by Lupin Pharmaceuticals, the drug maker said Tuesday.

Lupin announced the approval of levonorgestrel and ethinyl estradiol tablets in the 0.1 mg/0.02 mg strength, a generic version of Watson Labs' Lutera.

Lutera had sales of about $103.6 million during the 12-month period that ended in September 2012, according to IMS Health.

September 25, 2012

Generic drug maker Watson Labs recalled two lots of a prescription painkiller due to the potential for oversized and overly potent tablets, the company said.

PARSIPPANY, N.J. — Generic drug maker Watson Labs recalled two lots of a prescription painkiller due to the potential for oversized and overly potent tablets, the company said.

The drug maker announced the recall of hydrocodone bitartrate and acetaminophen tablets in the 10 mg/500 mg strengths based on a customer complaint of tablets that were thicker and darker-colored than the others.

March 16, 2012

Another generic drug maker has joined efforts to challenge the patent on a drug made by Forest Labs for treating hypertension.

NEW YORK — Another generic drug maker has joined efforts to challenge the patent on a drug made by Forest Labs for treating hypertension.

March 14, 2012

Forest Labs has filed suit against Glenmark Generics and several other companies, alleging that they infringed on its patent for a drug to treat hypertension by seeking regulatory approval for generic versions.

NEW YORK — Forest Labs has filed suit against Glenmark Generics and several other companies, alleging that they infringed on its patent for a drug to treat hypertension by seeking regulatory approval for generic versions.

Forest and Johnson & Johnson subsidiary Janssen Pharmaceutica NV have sued Glenmark, Hetero USA, Torrent Pharmaceuticals and Watson Labs in response to their filing regulatory approval applications with the Food and Drug Administration for generic versions of Bystolic (nebivolol).

February 8, 2012

Subsidiaries of Watson Pharmaceuticals and Johnson & Johnson have settled a lawsuit filed by the latter when Watson attempted to market a generic version of one of its contraceptive drugs.

PARSIPPANY, N.J. — Subsidiaries of Watson Pharmaceuticals and Johnson & Johnson have settled a lawsuit filed by the latter when Watson attempted to market a generic version of one of its contraceptive drugs.

November 29, 2011

Watson Pharmaceuticals subsidiary Watson Labs has received regulatory approval for a generic oral contraceptive.

PARSIPPANY, N.J. — Watson Pharmaceuticals subsidiary Watson Labs has received regulatory approval for a generic oral contraceptive.

Watson Labs said its abbreviated new drug application for Vestura (3-mg drospirenone and 0.02-mg ethinyl estradiol) was approved by the Food and Drug Administration.

Watson currently is involved in patent litigation with Bayer concerning the product, which is a generic version of Bayer's Yaz oral contraceptive product.

November 11, 2011

Watson Pharmaceuticals is challenging Swiss drug maker Novartis' patent on a drug used to treat dementia, Watson said.

PARSIPPANY, N.J. — Watson Pharmaceuticals is challenging three of Swiss drug maker Novartis' patents on a drug used to treat dementia, Watson said.

The company said subsidiary Watson Labs had filed for approval generic rivastigmine transdermal system patches in the 4.6-mg and 9.5-mg strengths, both designed to last for 24 hours, with the Food and Drug Administration. The patches are used to treat mild to moderate dementia associated with Alzheimer's or Parkinson's disease.

September 13, 2011

Watson Labs has begun shipping a drug designed to treat partial onset seizures in patients with epilepsy.

MORRISTOWN, N.J. — Watson Labs has begun shipping a drug designed to treat partial onset seizures in patients with epilepsy.

The drug maker said it launched levetiracetam extended-release tablets in the 500-mg and 750-mg strengths. The drug is a generic version of UCB's Keppra XR. The drug is indicated to treat patients ages 16 years and older.

Watson said it began shipping the drug on Tuesday following approval of its abbreviated new drug application from the Food and Drug Administration.

June 21, 2011

Watson subsidiary Watson Labs is seeking approval for a drug designed to treat symptomatic benign prostatic hyperplasia in men with an enlarged prostate.

PARSIPPANY, N.J. — Watson subsidiary Watson Labs is seeking approval for a drug designed to treat symptomatic benign prostatic hyperplasia in men with an enlarged prostate.

The company filed an abbreviated new drug application to market dutasteride capsules in the 0.5-mg strength. The drug is a generic version of Avodart, which is made by GlaxoSmithKline.

June 3, 2011

Generic drug maker Watson Labs is hoping to market a generic version of a Pfizer drug for erectile dysfunction.

PARSIPPANY, N.J. — Generic drug maker Watson Labs is hoping to market a generic version of a Pfizer drug for erectile dysfunction.

Watson announced Thursday that it had filed a regulatory approval application with the Food and Drug Administration to market a generic version of Viagra (sildenafil citrate) tablets in 25-mg, 50-mg and 100-mg strengths.

May 2, 2011

Watson Pharmaceuticals has launched an authorized generic version of a Johnson & Johnson drug for treating attention deficit hyperactivity disorder through a subsidiary, Watson said Monday.

PARSIPPANY, N.J. — Watson Pharmaceuticals has launched an authorized generic version of a Johnson & Johnson drug for treating attention deficit hyperactivity disorder through a subsidiary, Watson said Monday.

Watson announced the launch by Watson Labs of methylphenidate hydrochloride extended-release tablets under an agreement with J&J subsidiary Ortho-McNeil-Janssen.

April 8, 2011

Watson announced that its subsidiary is seeking approval to market a generic version of a bacterial conjunctivitis treatment.

PARSIPPANY, N.J. — Watson announced that its subsidiary is seeking approval to market a generic version of a bacterial conjunctivitis treatment.

Watson Labs filed an abbreviated new drug application with the Food and Drug Administration for moxifloxacin hydrochloride ophthalmic solution USP in the 0.5% strength. The antibiotic solution is a generic version of Alcon's Vigamox, which had total U.S. sales of about $281 million ended in February, according to IMS Health.

March 22, 2011

A subsidiary of Watson Pharmaceuticals has launched a treatment for herpes infections, the company said Monday.

MORRISTOWN, N.J. — A subsidiary of Watson Pharmaceuticals has launched a treatment for herpes infections, the company said Monday.

Watson Labs launched famciclovir tablets in the 125-mg, 250-mg and 500-mg strengths. The drug is a generic version of Novartis’ Famvir and is used to treat cold sores and genital herpes in patients with and without HIV.

Famvir and generic versions had sales of about $197 million in 2010, according to IMS Health.

February 25, 2011

Watson Labs is hoping to be the first to market a generic version of a popular drug for attention deficit hyperactivity disorder.

PHILADELPHIA — Watson Labs is hoping to be the first to market a generic version of a popular drug for attention deficit hyperactivity disorder.

British drug maker Shire announced Thursday that it had received notification that Watson filed for regulatory approval of a version of Adderall XR (dextroamphetamine and amphetamine) capsules with the Food and Drug Administration. Watson’s application contained a Paragraph IV certification, a legal assertion that the patent covering Adderall XR is invalid, unenforceable or won’t be infringed by Watson’s product.

January 26, 2011

Watson Pharmaceuticals is seeking regulatory approval for a generic drug for high cholesterol.

MORRISTOWN, N.J. — Watson Pharmaceuticals is seeking regulatory approval for a generic drug for high cholesterol.

Watson, through subsidiary Watson Labs, said it applied for approval of a generic version of Daiichi Sankyo’s and Genzyme’s Welchol (colesevelam hydrochloride). The drug, a powdered oral suspension, is used to reduce “bad” LDL cholesterol in patients with primary hyperlipidemia, either alone or in combination with a statin.

December 16, 2010

A subsidiary of Watson Pharmaceuticals has entered a licensing agreement with a subsidiary of Hungarian drug maker Richter to develop and market a drug for uterine fibroids, the two companies said Thursday.

MORRISTOWN, N.J. — A subsidiary of Watson Pharmaceuticals has entered a licensing agreement with a subsidiary of Hungarian drug maker Richter to develop and market a drug for uterine fibroids, the two companies said Thursday.

Watson Labs and PregLem said European studies had shown Esmya (ulipristal acetate) to be a safe and effective treatment for the disease, a benign tumor condition that affects between one-fifth and one-fourth of women of reproductive age worldwide. Watson expected to start phase-3 studies of the drug in the United States in 2011.

October 6, 2010

Watson Pharmaceuticals has settled a patent lawsuit with Endo Pharmaceuticals concerning an Endo prescription painkiller,...

MORRISTOWN, N.J. Watson Pharmaceuticals has settled a patent lawsuit with Endo Pharmaceuticals concerning an Endo prescription painkiller, Watson said Thursday.

 

The generic drug maker said its subsidiary, Watson Labs, had received a royalty-free license to Endo’s patents covering the extended-release painkiller Opana ER (oxymorphone).

 

 

Watson will have the right to launch its version of the drug in September 2012. Other details of the settlement were not disclosed, Watson said.

 

October 4, 2010

Generic drug maker Watson Pharmaceuticals is seeking approval for a generic treatment for Parkinson’s disease,...

MORRISTOWN, N.J. Generic drug maker Watson Pharmaceuticals is seeking approval for a generic treatment for Parkinson’s disease, prompting a lawsuit from the drug’s manufacturer.

 

Watson said Tuesday that Watson Labs, a subsidiary of the company, had filed for approval for rasagiline mesylate tablets, a treatment for Parkinson’s used either alone or with the drug levodopa. The drug is a generic version of Teva Neuroscience’s Azilect.

 

 

September 6, 2010

Generic drug maker Watson Pharmaceuticals has applied for Food and Drug Administration approval for a...

MORRISTOWN, N.J. Generic drug maker Watson Pharmaceuticals has applied for Food and Drug Administration approval for a version of a drug used to treat eye diseases, Watson said Tuesday.

June 7, 2010

The wholesale drug industry’s leading trade group tapped 10 pharmaceutical and consumer product manufacturers this...

May 4, 2010

A subsidiary of Watson Pharmaceuticals is challenging the patent to a drug for high cholesterol,...